CROSS-STANDARD public interest · Home/clinical medical device

China-to-EU Medical Device Compliance Gap Matrix

AI-compiled from official public sources — cross-checked by multiple AI models, not human-verified. Informational only; see disclaimer. Public-interest, source-linked comparison of common China home and clinical medical device documentation against EU MDR 2017/745 conformity, Notified Body, EU Authorised Representative, EUDAMED, UDI, ISO 13485, and electrical-safety expectations.

Dataset 2026-06-11 Last verified 2026-06-11 12 rows

GAP MATRIX

Compliance Gap Matrix

Gap matrix
Compliance item Common China baseline European Union (MDR) Gap / action Source + verification date
MDR Device Classification — Annex VIII Rules China NMPA classifies medical devices into Class I (lowest risk, filing only), Class II (moderate risk, NMPA provincial registration), and Class III (highest risk, NMPA national registration) under the Administrative Measures for the Registration and Filing of Medical Devices (2021). Classification is determined by the NMPA Classification Catalogue (医疗器械分类目录). Home-use devices may fall in Class I or II; clinical devices commonly reach Class II or III.医疗器械注册与备案管理办法 (2021, NMPA Order No. 47)
医疗器械分类目录 (2017, NMPA Announcement No. 104; amended by subsequent announcements including Announcement No. 132 of 2025, effective Jan 2026, adjusting 31 categories — always verify current edition)
医疗器械监督管理条例 (2021, State Council Order No. 739)		 EU MDR (2017/745) Annex VIII establishes 22 classification rules (Rules 1–22) that assign devices to Class I, IIa, IIb, or III based on intended purpose, invasiveness, duration of contact, and whether the device supplies energy or medicinal substances. Class I devices may self-certify (except where sterility or measuring function applies); Class IIa/IIb/III require a Notified Body assessment. The classification directly determines the conformity assessment route under Annex IX, X, or XI.Regulation (EU) 2017/745 (MDR), Annex VIII — Classification Rules
Regulation (EU) 2017/745 (MDR), Articles 51–54 — Classification Procedure
MDCG 2021-24 Rev.1 Guidance on Classification of Medical Devices (April 2026) — official EC document at health.ec.europa.eu		 The MDR Annex VIII rules and NMPA classification criteria are independent systems with different logic; the same device may receive different risk classes under each. A device classified as Class II by NMPA may be Class IIb or III under MDR (triggering a mandatory Notified Body audit), or vice versa. Exporters must independently determine the MDR class — NMPA registration class cannot be assumed to map directly. Misclassification under MDR is a market-access blocker.Manufacturers must apply MDR Annex VIII rules to determine the EU device class independently of any NMPA classification held. The resulting class dictates whether a Notified Body is required and which conformity assessment annex applies. This determination is a foundational step before any EU market-access activity. European Parliament and Council / EUR-Lex2026-06-11 · unverified
MDR Conformity Assessment Route Determined by Device Class Under the 2021 NMPA Administrative Measures, conformity routes track device class: Class I devices file with provincial NMPA (no technical review required); Class II devices register with provincial NMPA with technical dossier review; Class III devices register with national NMPA with full technical review including clinical evaluation. Quality Management System certification (YY/T 0287, equivalent to ISO 13485) is required for Class II and III registration. There is no direct equivalent to a Notified Body — the NMPA itself is the reviewing authority.医疗器械注册与备案管理办法 (2021, NMPA Order No. 47)
医疗器械生产质量管理规范 (GMP for Medical Devices, NMPA Order No. 64, 2014; superseded by NMPA Order No. 107, issued Nov 2025, effective 1 Nov 2026 — both versions require QMS conformity; exporters must plan transition)
YY/T 0287-2017 (equivalent to ISO 13485:2016) — Medical Devices Quality Management Systems		 Once device class is determined under MDR Annex VIII, the conformity assessment route is fixed by Articles 52–54 and Annexes IX–XI. Class I (general): manufacturer self-assessment, Declaration of Conformity, no Notified Body. Class I (sterile / measuring function / reusable surgical): Notified Body involvement limited to those specific aspects. Class IIa: Annex IX (full QMS audit and technical documentation assessment) or Annex XI Part A (product conformity verification — examination and testing of products) + Annex XI Part B. Class IIb: Annex IX or Annex X (EU type-examination) + Annex XI. Class III: Annex IX or Annex X (EU type-examination) + Annex XI, with design dossier scrutiny. Notified Bodies are designated by national competent authorities and listed on the NANDO database; they must also be registered in EUDAMED.Regulation (EU) 2017/745 (MDR), Articles 52–54 — Conformity Assessment Procedures
Regulation (EU) 2017/745 (MDR), Annex IX — Conformity Assessment based on a Quality Management System and Assessment of Technical Documentation
Regulation (EU) 2017/745 (MDR), Annex X — Conformity Assessment based on Type-Examination
Regulation (EU) 2017/745 (MDR), Annex XI — Conformity Assessment based on Product Conformity Verification		 China has no Notified Body system; NMPA is the sole competent authority. EU MDR requires an independent EU-designated Notified Body for all classes above I (general). A Chinese manufacturer with Class II NMPA registration only has no equivalent EU Notified Body certification — a full MDR conformity assessment engagement must be initiated from scratch. Industry-reported average for a successful MDR certification is 13–18 months; complex or Class III devices can extend to 24+ months, plus a 6–12 month NB waiting-list period before assessment even begins (Commission Implementing Regulation (EU) 2026/977, published May 2026, sets legally binding maximum timelines per audit phase).The MDR conformity assessment route is determined solely by the device class assigned under Annex VIII and cannot be substituted by NMPA registration. Manufacturers targeting the EU market must engage an EU-designated Notified Body for any device above Class I (general), independent of any existing Chinese regulatory status. Early Notified Body selection is advisable given reported capacity constraints in the EU. European Parliament and Council / EUR-Lex2026-06-11 · unverified
Conformity Assessment Route by Risk Class Under China NMPA regulations, medical devices are classified into Class I, II, and III. Class I devices require filing (record) with local NMPA. Class II devices require provincial NMPA registration with technical review. Class III devices require national NMPA registration including technical review, clinical evaluation, and on-site inspection. There is no independent third-party Notified Body system; assessment is conducted by government-designated review centers (e.g., CMDE).醫療器械監督管理條例 (State Council Order No. 739, 2021)
醫療器械注冊與備案管理辦法 (NMPA Order No. 47, 2021)
醫療器械臨床評價技術指導原則 (NMPA 2021 guidance)		 Under EU MDR 2017/745, Class I devices may self-declare conformity (except sterile, measuring, or reusable surgical instruments which require partial NB involvement). Class IIa, IIb, and III devices must undergo conformity assessment by a designated Notified Body, covering technical documentation (Annex II or III) and quality management system audit. Class III and certain Class IIb devices additionally require an EU-type examination (Annex X).EU MDR 2017/745, Article 52 (Conformity assessment procedures)
EU MDR 2017/745, Annex II (Technical Documentation)
EU MDR 2017/745, Annex III (Technical Documentation on Post-Market Surveillance)
EU MDR 2017/745, Annex X (EU Type-Examination)
EU MDR 2017/745, Annex XI (Conformity Assessment based on Product Conformity Verification)		 EU MDR requires an independent, EU-designated Notified Body to audit technical documentation and QMS for Class IIa and above — a body that operates under accreditation and designation under EU law and is entirely separate from NMPA. Chinese manufacturers must identify, apply to, and pass audit by an EU NB (often 12–36 months), which is an additional layer with no direct NMPA equivalent. NMPA registration does not substitute for NB conformity assessment under MDR.[INFORMATIONAL] Chinese manufacturers holding NMPA registration must still engage an EU Notified Body for Class IIa and above devices. NMPA approval does not satisfy MDR Article 52 requirements. This gap represents one of the most significant process and timeline differences for China-to-EU market access. EUR-Lex / Official Journal of the European Union2026-06-11 · unverified
Clinical Evaluation under MDR (Annex XIV) China NMPA requires clinical evaluation for Class II and III devices, which may be satisfied by clinical trial data, literature review, or equivalence to an already-registered device. Class I devices generally do not require clinical evaluation. NMPA clinical trials must be conducted at NMPA-qualified clinical trial institutions within China. The equivalence pathway is available but NMPA applies its own criteria distinct from MDR Annex XIV.醫療器械臨床評價技術指導原則 (NMPA 2021)
醫療器械臨床試驗質量管理規範 (NMPA/NHFPC 2016)
醫療器械監督管理條例 (State Council Order No. 739, 2021), Article 24		 EU MDR Annex XIV requires a clinical evaluation for all medical devices regardless of class, demonstrating safety and performance through a systematic review of clinical data (literature, clinical investigations, or equivalence data). The clinical evaluation report (CER) must be updated throughout the device lifecycle and reviewed by the Notified Body for Class IIa and above. Clinical investigations under MDR must comply with Articles 62–82 and Annex XV.EU MDR 2017/745, Annex XIV (Clinical Evaluation and Post-Market Clinical Follow-up)
EU MDR 2017/745, Articles 61–82 (Clinical Evaluation and Investigation)
MDCG 2020-5 (Guidance on Clinical Evaluation)
MDCG 2020-6 (Guidance on Sufficient Clinical Evidence for Legacy Devices)		 MDR Annex XIV imposes a more rigorous and explicit clinical evaluation methodology than NMPA, including mandatory post-market clinical follow-up (PMCF) and equivalence criteria that are stricter (requiring identical manufacturer and legally documented access to the equivalent device's technical file). Clinical data generated solely under NMPA requirements may not meet MDR standards without supplementation. The CER must be maintained continuously and is subject to NB scrutiny — an ongoing obligation with no direct NMPA parallel.[INFORMATIONAL] Existing NMPA clinical data may partially support an MDR clinical evaluation but is unlikely to be sufficient alone, particularly for PMCF obligations and the stricter equivalence pathway. Manufacturers should plan for supplementary clinical evidence generation or additional literature review aligned to MDR Annex XIV methodology. EUR-Lex / Official Journal of the European Union2026-06-11 · unverified
Quality Management System (QMS) Requirements for CE Marking China requires medical device manufacturers to establish a quality management system compliant with the 醫療器械生產質量管理規範 (YY/T 0287 or GMP for medical devices). Class III manufacturers are subject to on-site inspection by NMPA or provincial authorities. China's QMS framework is broadly analogous to ISO 13485 but enforced through domestic regulation and NMPA inspection rather than third-party NB audit.醫療器械生產質量管理規範 (NMPA Order No. 64, 2014); superseded by NMPA Order No. 107 (issued Nov 2025, effective Nov 2026)
YY/T 0287-2017 (equivalent to ISO 13485:2016)
醫療器械監督管理條例 (State Council Order No. 739, 2021), Articles 19–23		 EU MDR Article 10(9) requires all manufacturers of medical devices (all classes) to implement a QMS covering the full device lifecycle, including design, production, post-market surveillance (Articles 83–86), and vigilance (Articles 87–92). MDR does not legally mandate ISO 13485 certification — EN ISO 13485:2016 is the harmonised voluntary standard that provides a recognised evidence route for QMS conformity. For Class IIa, IIb, and III devices, the Notified Body audits the QMS under Annex IX (full QMS) or Annex XI (product conformity verification). A Declaration of Conformity and CE marking are issued only after successful NB assessment.EU MDR 2017/745, Article 10(9) (Quality Management System)
EU MDR 2017/745, Annex IX (Conformity Assessment based on a Quality Management System and on Assessment of Technical Documentation)
EU MDR 2017/745, Annex XI (Conformity Assessment based on Product Conformity Verification)
ISO 13485:2016 (Medical devices — Quality management systems)		 While both systems require a QMS broadly aligned with ISO 13485, MDR mandates an independent Notified Body audit of the QMS — a recurring obligation (typically annual surveillance audits plus recertification every 5 years). NMPA QMS inspection is a government function, not a separate accredited third-party audit. Chinese manufacturers must budget for NB audit fees (which can be substantial), prepare English-language QMS documentation, and maintain the NB relationship on an ongoing basis — none of which is required for NMPA compliance.[INFORMATIONAL] An existing ISO 13485-certified QMS provides a strong foundation but does not automatically satisfy MDR Annex IX or XI requirements. Manufacturers must engage an EU Notified Body to formally audit and certify the QMS under MDR, and must sustain annual surveillance audits. This is an ongoing cost and process commitment distinct from NMPA obligations. EUR-Lex / Official Journal of the European Union2026-06-11 · unverified
EU Market Access — CE Marking under MDR 2017/745 In China, medical devices must be registered with the National Medical Products Administration (NMPA) before market placement. Class II devices require provincial-level NMPA registration; Class III requires national NMPA registration. Registration requires technical dossier (including clinical data — either clinical trial or clinical literature evaluation), product standard (YY/T or GB/T), and quality management system certification (ISO 13485 or YY/T 0287 equivalent). No independent authorised representative system; the Chinese legal manufacturer or the local agent/legal entity bears regulatory responsibility. No EUDAMED equivalent; China operates the NMPA National Medical Device Registration Information Service platform (国家医疗器械注册信息服务平台).医疗器械监督管理条例 (State Council Order No. 739, 2021)
医疗器械注册与备案管理办法 (NMPA Order No. 47, 2021)
YY/T 0287 / ISO 13485 Quality Management System
临床评价技术指导原则 (NMPA 2021 clinical evaluation guidance)		 Medical devices placed on the EU market must bear CE marking under Regulation (EU) 2017/745 (MDR). Class IIa and above require a Notified Body (NB) conformity assessment certificate. Manufacturers must also: (1) designate an EU Authorised Representative if based outside the EU; (2) register as an actor in EUDAMED and register the device/UDI in EUDAMED before placing on the market (actor registration and UDI/device registration modules became legally mandatory from 28 May 2026 per Commission Decision (EU) 2025/2371); (3) prepare Technical Documentation per Annex II (general technical documentation) and Annex III (technical documentation on post-market surveillance); (4) prepare a Clinical Evaluation Report (CER) and Post-Market Clinical Follow-up (PMCF) plan per Annex XIV; (5) implement a Post-Market Surveillance (PMS) system including PSUR or periodic safety update (Articles 83–86); (6) importers and distributors carry their own obligations under Articles 13–14 including checking CE marking, labelling, and NB certificate validity before supply.Regulation (EU) 2017/745 (MDR) — Articles 10, 11, 13, 14, 51–58
Regulation (EU) 2017/745 (MDR) — Annex II (Technical Documentation)
Regulation (EU) 2017/745 (MDR) — Annex III (Technical Documentation on Post-Market Surveillance)
Regulation (EU) 2017/745 (MDR) — Annex XIV (Clinical Evaluation and Post-Market Clinical Follow-up)
Commission Implementing Regulation (EU) 2021/2078 (EUDAMED operational rules)
Commission Decision (EU) 2025/2371 (EUDAMED mandatory date: 28 May 2026)
MDCG 2020-1 (Clinical Evaluation guidance)
MDCG 2019-16 (UDI guidance)		 The EU MDR framework is substantially heavier than NMPA registration. Key gaps for a Chinese manufacturer entering the EU: (1) Mandatory Notified Body involvement for Class IIa+ — no NB equivalent in China; NB audits are lengthy and costly (industry-reported average 13–18 months for successful MDR certification; 24+ months for complex/Class III devices; plus 6–12 month NB waiting-list before assessment begins; Commission Implementing Regulation (EU) 2026/977 sets legally binding max timelines per audit phase). (2) EU Authorised Representative must be a legal entity in an EU/EEA member state — a distinct role with legal liability; China has no direct equivalent. (3) EUDAMED registration (actor + device + UDI) is a new EU-specific digital system with no Chinese counterpart. (4) Clinical Evaluation under MDR Annex XIV requires comprehensive clinical data strategy often exceeding NMPA clinical literature evaluation norms, particularly for implantables and Class III. (5) Post-market obligations (PSUR, PMCF, vigilance reporting) are more prescriptive under MDR. (6) Importer/distributor obligations under MDR Articles 13–14 impose supply-chain compliance checks absent from NMPA framework.For informational reference only. A Chinese medical device manufacturer wishing to access the EU market must comply with the full MDR 2017/745 package: NB conformity assessment (Class IIa+), EU Authorised Representative appointment, EUDAMED actor and device/UDI registration, comprehensive Technical Documentation and Clinical Evaluation, and post-market surveillance obligations. This is considerably more burdensome than NMPA registration alone. Consult a qualified EU regulatory affairs professional and a Notified Body for device-specific guidance. EUR-Lex / Official Journal of the European Union2026-06-11 · unverified
Quality Management System (QMS) — ISO 13485 under EU MDR In China, the equivalent framework is the NMPA Medical Device Good Manufacturing Practice (医疗器械生产质量管理规范, GMP), issued by NMPA (formerly CFDA). Many Chinese manufacturers also hold ISO 13485 certification. NMPA GMP covers QMS structure, document control, production and process controls, inspection, and CAPA. However, CN GMP does not directly require EU-style post-market surveillance reporting or Notified Body audits, and its clinical/technical documentation requirements differ from EU MDR.医疗器械生产质量管理规范 (NMPA GMP) — Order No. 64 (2014); superseded by NMPA Order No. 107 (issued Nov 2025, effective Nov 2026)
ISO 13485:2016 (widely adopted by CN exporters)
医疗器械监督管理条例 (Regulations on the Supervision and Administration of Medical Devices, State Council Order No. 739)		 EU MDR (Regulation 2017/745) Article 10(9) requires all manufacturers of medical devices to implement a Quality Management System (QMS) that covers the full device lifecycle. MDR does not legally require ISO 13485 certification — EN ISO 13485:2016 is the harmonised standard that provides a voluntary but widely-used evidence route for demonstrating QMS conformity. For Class IIa and above devices, the QMS must be audited by an EU Notified Body under Annex IX or XI. The QMS must encompass a post-market surveillance (PMS) system (Articles 83–86) and a vigilance system with mandatory incident reporting to national competent authorities (Articles 87–92). Technical documentation, clinical evaluation, and risk management records must be maintained within the QMS.EU MDR Regulation (EU) 2017/745, Article 10(9) (QMS obligation — all manufacturers)
EN ISO 13485:2016 — harmonised standard for MDR QMS (voluntary certification; evidence route for Art 10(9) compliance)
EU MDR Annex IX (QMS conformity assessment for Class IIa/IIb/III)
EU MDR Articles 83–86 (Post-Market Surveillance)
EU MDR Articles 87–92 (Vigilance)		 Key gaps for Chinese manufacturers targeting EU market: (1) ISO 13485 certification alone is insufficient — MDR requires conformity assessment by an EU Notified Body for Class IIa and above; (2) EU MDR mandates a specific Post-Market Surveillance (PMS) system with periodic safety update reports (PSUR) and post-market clinical follow-up (PMCF), which exceed CN GMP requirements; (3) EU MDR vigilance system requires mandatory reporting of serious incidents and field safety corrective actions (FSCAs) to EU national competent authorities within strict timelines (2/10/30 days); (4) Technical documentation must meet MDR Annex II/III format, not just NMPA format; (5) QMS records must be maintained in EU-accessible format for audit by Notified Body. Chinese ISO 13485 and GMP certification provide a strong foundation but significant MDR-specific additions are required.[INFORMATIONAL ONLY] Chinese manufacturers holding both NMPA GMP compliance and ISO 13485 certification have a strong QMS foundation, but must implement significant MDR-specific additions — particularly Notified Body audit (Class IIa+), EU-format PMS/PSUR/PMCF system, and EU vigilance reporting — before CE marking under MDR is achievable. This is not legal advice; consult a regulatory affairs specialist and an EU Notified Body. European Parliament and of the Council — EUR-Lex2026-06-11 · unverified
Electrical Safety — EN 60601-1 (harmonised under EU MDR) GB 9706.1-2020 is China's national mandatory standard for general requirements for basic safety and essential performance of medical electrical equipment, aligned to IEC 60601-1 Ed.3 with minor Chinese deviations. It became mandatory for new NMPA registrations from 2023-05-01. Testing must be performed by a CNAS-accredited or NMPA-designated laboratory. Because both GB 9706.1-2020 and EN 60601-1 derive from IEC 60601-1 Ed.3, a substantial portion of the physical test data (leakage current, dielectric withstand, insulation) can be shared or cross-referenced, but a separate Chinese test report to GB 9706.1-2020 is still required by NMPA, and the EU harmonised-standard declaration citing EN 60601-1 under MDR must be produced independently.GB 9706.1-2020 — Medical electrical equipment — Part 1: General requirements for basic safety and essential performance (aligned to IEC 60601-1 Ed.3, mandatory from 2023-05-01)
NMPA Medical Device Registration Regulations (Order No. 47, 2021)
NMPA Technical Review Guidelines for Medical Electrical Equipment Safety		 EN 60601-1:2006+A1:2013+A12:2014+A2:2021 (with European deviations from IEC 60601-1) is the primary harmonised standard for general electrical safety of medical electrical equipment under Regulation (EU) 2017/745 (MDR). Use of harmonised standards is voluntary under MDR Article 8, but conformity to a harmonised standard listed in the Official Journal of the EU (OJ) creates a presumption of conformity with the MDR General Safety and Performance Requirements (GSPR) it covers. Manufacturers must additionally apply applicable particular standards (EN 60601-2-x series) for specific device types. A technical file or design dossier must include a harmonised-standard declaration referencing the applicable EN 60601 versions used, supported by test reports from an ISO 17025-accredited laboratory or a Notified Body. The harmonised standards list under MDR is published and updated periodically on EUR-Lex.EN 60601-1:2006+A1:2013+A12:2014+A2:2021 — Medical electrical equipment — Part 1: General requirements for basic safety and essential performance (harmonised under MDR; voluntary route creating presumption of conformity under MDR Article 8)
EN 60601-2-x particular standards series (device-type specific, harmonised where applicable under MDR)
Regulation (EU) 2017/745 — Medical Device Regulation (MDR), Annex I (GSPR)
Commission Decision (EU) and OJ C series — Harmonised Standards List under MDR (updated periodically on EUR-Lex)		 Both standards derive from IEC 60601-1 Ed.3, so physical test parameters overlap significantly. Key gaps: (1) EU requires a formal harmonised-standard declaration citing EN 60601-1 under MDR Annex I GSPR — a Chinese GB 9706.1 test report alone does not satisfy this; (2) EU MDR mandates a clinical evaluation and risk management file (ISO 14971) linked to the GSPR, which NMPA registration does not fully mirror; (3) Applicable EN 60601-2-x particular standards may differ from Chinese YY/T or GB equivalents; (4) Notified Body involvement is required for Class IIb/III devices in the EU, whereas NMPA uses its own designated testing institutes; (5) European Authorised Representative (EAR) and EUDAMED registration are mandatory for EU market entry with no CN equivalent.[INFORMATIONAL ONLY] A device already certified to GB 9706.1-2020 has a strong technical foundation for EN 60601-1:2006+A1:2013+A12:2014+A2:2021 compliance given common IEC 60601-1 parentage, but cannot rely on the Chinese certificate alone for EU MDR. Separate EN 60601-1 test reports, a harmonised-standard declaration, and full MDR technical documentation (clinical evaluation, risk management per ISO 14971, QMS per ISO 13485) must be produced for the EU. Engage a Notified Body early for Class IIb/III devices. This is informational; seek qualified regulatory counsel before submission. European Commission DG SANTE — MDR Harmonised Standards List (Commission Implementing Decision (EU) 2021/1182); IEC; SAMR/SAC (China) for GB 9706.1-20202026-06-11 · unverified
EMC for Medical Electrical Equipment — EN 60601-1-2 (harmonised under EU MDR) YY 9706.102-2021 is China's national standard for EMC of medical electrical equipment, aligned to IEC 60601-1-2:2007 (Ed.3.0, with minor Chinese deviations), not IEC 60601-1-2 Ed.4. It became effective 2023-07-01 and mandatory for new NMPA registrations from that date, replacing YY 0505-2012. Like EN 60601-1-2, it covers emissions and immunity, but its IEC Ed.3.0 basis means EU Ed.4 evidence may require gap analysis and supplemental testing. A separate Chinese test report to YY 9706.102-2021 by a CNAS or NMPA-designated lab is still required for NMPA registration, and the EU technical documentation route under MDR must be produced independently.YY 9706.102-2021 — Medical electrical equipment — Part 1-2: General requirements for basic safety and essential performance — Collateral standard: Electromagnetic disturbances — Requirements and tests (aligned to IEC 60601-1-2:2007 Ed.3.0, mandatory from 2023-07-01)
NMPA Medical Device Registration Regulations (Order No. 47, 2021)
YY 0505-2012 — superseded predecessor (Ed.3-based, no longer accepted for new registrations)		 EN 60601-1-2:2015 (4th edition, identical to IEC 60601-1-2 Ed.4) is the primary collateral standard for electromagnetic compatibility (EMC) of medical electrical equipment and systems. It sets requirements for emissions (radiated and conducted) and immunity (ESD, radiated RF, fast transients, surge, conducted RF, magnetic fields, voltage dips/interruptions) and introduces an Electromagnetic Disturbance Risk Management process tied to ISO 14971. Ed.4 is significantly more stringent than Ed.3: immunity test levels for professional healthcare facilities and home healthcare environments differ, and manufacturers must declare the Intended Electromagnetic Environment. NOTE: As of June 2026, EN 60601-1-2:2015 has not been officially listed as a harmonised standard under MDR 2017/745 in the Official Journal (Commission Implementing Decision (EU) 2021/1182 and subsequent amendments do not include EN 60601-1-2). Manufacturers must address the EMC GSPR directly or via an alternative compliance route; conformity with IEC 60601-1-2 Ed.4 is strongly expected by Notified Bodies even without a formal harmonised-standard presumption.EN 60601-1-2:2015 (IEC 60601-1-2 Ed.4) — Medical electrical equipment — Part 1-2: General requirements for basic safety and essential performance — Collateral standard: Electromagnetic disturbances — Requirements and tests (NOT yet listed as harmonised under MDR as of June 2026; address EMC GSPR directly)
Regulation (EU) 2017/745 — MDR, Annex I GSPR Chapter II (safety and performance requirements)
Commission Implementing Decision (EU) 2021/1182 and amendments — Harmonised Standards List under MDR (EN 60601-1-2 not included; consult EUR-Lex for current list)		 EN 60601-1-2:2015 is based on IEC 60601-1-2 Ed.4, while YY 9706.102-2021 aligns to IEC 60601-1-2:2007 Ed.3.0. Key gaps: (1) EU evidence to Ed.4 may require a documented gap analysis against the Ed.3.0-based YY standard for China, and Chinese YY evidence alone does not satisfy EU EMC expectations; (2) EU MDR links EMC compliance to the overall electromagnetic disturbance risk management process (ISO 14971) within the technical file — NMPA dossiers do not require the same integrated risk-linkage depth; (3) Intended Electromagnetic Environment categories, immunity levels, and labelling requirements differ materially between Ed.3.0 and Ed.4; (4) For EU, an ISO 17025-accredited lab or Notified Body is expected; for CN, a CNAS or NMPA-designated lab is required — different accreditation bodies; (5) EUDAMED registration and EU Authorised Representative have no CN parallel.[INFORMATIONAL ONLY] A device already tested to YY 9706.102-2021 (aligned to IEC 60601-1-2:2007 Ed.3.0) may have partial test-data overlap with EN 60601-1-2 requirements, but Ed.4 differences require documented gap analysis and potentially supplemental testing for EU. Since EN 60601-1-2 is not officially harmonised under MDR as of June 2026, manufacturers cannot claim a formal harmonised-standard presumption; instead, test reports to IEC 60601-1-2 Ed.4 must be documented in the technical file as evidence of GSPR compliance, alongside the integrated electromagnetic disturbance risk management file per ISO 14971. Reports should be from an ISO 17025-accredited laboratory. This is informational; seek qualified regulatory counsel before submission. European Commission DG SANTE — MDR Harmonised Standards List; IEC (International Electrotechnical Commission); NMPA/SAMR (China) for YY 9706.102-20212026-06-11 · unverified
UDI Assignment & Labelling NMPA UDI system (effective 2021 onwards, phased by class) requires Chinese manufacturers to assign a DI and PI, register in the NMPA UDI database, and apply the UDI carrier to the label. Issuing agencies are NMPA-recognised bodies (e.g. CMDC — 中国医疗器械行业协会).NMPA Order No. 19 (2019) — UDI System Rules
NMPA Announcement 2019 No. 10 — UDI Issuing Agency Accreditation		 EU MDR Article 27 requires manufacturers to assign a UDI (Basic UDI-DI + UDI-DI + UDI-PI) to every device and place it on the label. UDI carriers (AIDC + HRI) must appear on the device or packaging. Data must be uploaded to EUDAMED before placing on market.EU MDR 2017/745 Article 27
EU MDR 2017/745 Annex VI Part C
Commission Implementing Regulation (EU) 2021/2078		 EU MDR mandates uploading UDI data to EUDAMED (a pan-EU public database) before market placement — a step with no direct Chinese equivalent. The EU UDI-DI must be issued by an EU-designated issuing entity (GS1, HIBCC, ICCBBA). Chinese NMPA UDI codes are not accepted in the EU; a separate EU UDI must be obtained and EUDAMED registration completed independently.A Chinese manufacturer exporting to the EU must obtain a separate EU UDI from an EU-designated issuing agency (GS1, HIBCC, or ICCBBA), upload device data to EUDAMED (mandatory from 28 May 2026 per Commission Decision (EU) 2025/2371), and print the EU UDI carrier on labels. NMPA UDI registration does not substitute for any of these steps. EUR-Lex / Official Journal of the European Union2026-06-11 · unverified
EUDAMED Registration (Actors & Devices) China operates the NMPA Medical Device Registration Information Service (MDRIS). Manufacturers register products and establishments with NMPA/provincial bureaus. There is no single pan-national public actor registry comparable to EUDAMED's actor module; company registration is handled through SAMR (business license) separately.Regulations on the Supervision and Administration of Medical Devices (2021, State Council Order No. 739)
NMPA MDRIS system requirements		 EU MDR Articles 28–30 and Annex VI require all economic operators (manufacturers, authorised representatives, importers) and devices to be registered in EUDAMED before placing on the EU market. The manufacturer obtains a Single Registration Number (SRN). Device registration must include technical, clinical and UDI data. EUDAMED is the central EU traceability and vigilance database. The actor registration and UDI/device registration modules became legally mandatory from 28 May 2026 per Commission Decision (EU) 2025/2371; registrations made during the preceding voluntary phase are carried over.EU MDR 2017/745 Articles 28, 29, 30
EU MDR 2017/745 Annex VI Part A & B
Commission Implementing Regulation (EU) 2021/2078 (EUDAMED operational rules)		 EUDAMED requires a single integrated registration covering the actor (company), the device, UDI data, certificates, and post-market surveillance — all publicly searchable. China's system is fragmented across NMPA, SAMR and provincial bureaus, with no unified public actor portal. A Chinese manufacturer must separately register in EUDAMED as a manufacturer (or have its EU Authorised Representative do so) before CE-marked products can be placed on the EU market.A Chinese manufacturer must register in EUDAMED (actor module) to obtain an SRN, then register each device with full UDI and technical data before EU market placement — both obligations became legally mandatory from 28 May 2026 per Commission Decision (EU) 2025/2371. This obligation exists independently of NMPA registration and cannot be delegated away — though the EU Authorised Representative may assist in submission. European Commission — EUDAMED (DG SANTE)2026-06-11 · unverified
EU Authorised Representative, PRRC & Importer Obligations China requires foreign manufacturers to appoint a domestic agent (境内代理人) registered with NMPA, who acts as the regulatory contact and co-applicant for product registration. There is no direct equivalent to the PRRC role; quality management system responsibilities are assigned internally per ISO 13485 / YY/T 0287. Importers in China must obtain import licenses and verify product registration certificates.Regulations on the Supervision and Administration of Medical Devices (2021, State Council Order No. 739) Article 40
YY/T 0287-2017 (ISO 13485:2016 equivalent)
NMPA Measures for the Registration of Medical Devices (2021)		 EU MDR Article 11 mandates that any manufacturer not established in the EU must designate an EU Authorised Representative (AR) established in an EU member state, via written mandate. The AR co-signs regulatory submissions, is jointly liable with the manufacturer, and must be registered in EUDAMED. Article 15 requires manufacturers (and ARs) to have at least one Person Responsible for Regulatory Compliance (PRRC) with specified qualifications. EU importers (Article 13) must verify the manufacturer has an AR, that the device bears a CE mark and UDI, and maintain their own records.EU MDR 2017/745 Article 11 (Authorised Representative)
EU MDR 2017/745 Article 13 (Importer obligations)
EU MDR 2017/745 Article 15 (PRRC)
EU MDR 2017/745 Article 30 (EUDAMED registration of AR)		 The EU AR is a legal entity jointly liable under EU law — not merely an administrative agent. The PRRC must have documented qualifications (degree in natural sciences, medicine, pharmacy, engineering, or equivalent + at least one year of professional experience in regulatory or QA; or four years of relevant professional experience without the degree). Neither the Chinese domestic agent role nor internal QA staff automatically satisfy these EU obligations. A Chinese manufacturer must: (1) contract a qualified EU AR (commercial service or subsidiary in EU); (2) designate a PRRC meeting Article 15 criteria; (3) ensure EU importers fulfil Article 13 checks — all of which are additional costs and structural requirements with no NMPA equivalent.A Chinese manufacturer must appoint an EU Authorised Representative (a legal entity in an EU member state) via written mandate before accessing the EU market — the Chinese domestic agent does not satisfy this requirement (MDR Article 11). The manufacturer or AR must also have at least one qualified PRRC on record per Article 15 (degree in natural sciences, medicine, pharmacy, engineering or equivalent plus at least one year regulatory/QA experience; or four years relevant experience without the degree). These are mandatory structural obligations under EU MDR with no waiver mechanism, and represent the most operationally significant gap for Chinese exporters entering the EU. EUR-Lex / Official Journal of the European Union2026-06-11 · unverified

E-E-A-T

Named editorial review

Pending named reviewer

Official regulator, standards body, notified body, customs, or primary legal source preferred. Local PDFs are not accepted.

Editorial controls

Rows must include publisher, official URL, access date, verification flag, and last_verified before human_reviewed can be true.

SOURCES

Official-source register.